. 2010 Dec 8;22(2):155–165. doi: 10.1089/hum.2010.118

Table 3.

Serum hAAT Concentrations after Injection of rAAV1-CB-hAAT in C57BL/6 Mice

		Serum hAAT concentration (μM, mean ± SD) Dosage level (vg/kg)
Sex	Day	TFX 1.2 × 10¹³	HSV 1.2 × 10¹³	HSV 8 × 10¹³
Male	21	1.08 ± 1.57	1.08 ± 0.86	35.95 ± 9.18^b
	60	0.92 ± 0.44	2.65 ± 1.71^a	39.88 ± 8.95^b
	90	0.70 ± 0.25	1.51 ± 0.37	27.77 ± 5.60^b
Female	21	0.40 ± 0.25	1.08 ± 0.21^a	9.24 ± 2.34^b
	60	0.59 ± 0.14	1.40 ± 0.34^a	6.76 ± 0.52^b
	90	0.56 ± 0.03	0.80 ± 0.21	4.40 ± 1.27^b

^{^a}

Significantly different from TFX group, p < 0.01.

^{^b}

Significantly different from low-dose HSV group, p < 0.01.

hAAT, human alpha-1 anti-trypsin; HSV, recombinant herpes simplex-produced vector; SD, standard deviation; TFX, transfection-produced vector; vg, vector genomes.